Mir-138 overexpression also enhances osteosarcoma cell chemosensitivity to cisplatin by targeting EZH2. Thus, miR-138 could be a new therapeutic target for osteosarcoma treatment in the future. This evidence concerns the gene EZH2 and osteosarcoma.